![David Liu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Liu
Corporate Officer/Principal bei
Harvard University
Vermögen: 59 Mio $ am 31.07.2026
Profil
David R.
Liu is the founder of Ensemble Therapeutics Corp., founded in 2004, Permeon Biologics, Inc., founded in 2008, Editas Medicine, Inc., founded in 2013, and Exo Therapeutics, Inc., founded in 2018.
Dr. Liu is also the founder of nChroma Bio, Inc.,Prime Medicine, Inc.,Pairwise Plants Services, Inc...
Dr. Liu is currently a Professor at Harvard University.
Dr. Liu is currently an Associate Member at Massachusetts Institute of Technology.
Dr. Liu completed undergraduate education at Harvard University.
Dr. Liu earned a doctorate from the University of California, Berkeley.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PRIME MEDICINE, INC. 11,73 % | 31.03.2026 | 20.240.945 ( 11,73 % ) | 59 Mio $ | 31.07.2026 |
Aktive Positionen von David Liu
| Unternehmen | Position | Beginn |
|---|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 06.09.2011 |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Corporate Officer/Principal | 06.09.2011 |
Ehemalige bekannte Positionen von David Liu
| Unternehmen | Position | Ende |
|---|---|---|
| PRIME MEDICINE, INC. | Gründer | - |
Exo Therapeutics, Inc.
 Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs and small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes | Gründer | - |
Pairwise Plants Services
 Pairwise Plants Services Food: Major DiversifiedConsumer Non-Durables Engages in cultivation of crops | Gründer | - |
| EDITAS MEDICINE, INC. | Gründer | - |
Ausbildung von David Liu
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
99
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Ensemble Therapeutics Corp.
 Ensemble Therapeutics Corp. Chemicals: Major DiversifiedProcess Industries Develops novel classes of therapeutics and bioassays for research and diagnostics | Process Industries |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Permeon Biologics, Inc.
 Permeon Biologics, Inc. BiotechnologyHealth Technology Develops intracellular biotherapeutics platform to enhance drug delivery | Health Technology |
Editas Medicine, Inc.
 Editas Medicine, Inc. BiotechnologyHealth Technology Manufactures gene editing medicines | Health Technology |
Pairwise Plants Services
Pairwise Plants Services Food: Major DiversifiedConsumer Non-Durables Engages in cultivation of crops | Consumer Non-Durables |
Exo Therapeutics, Inc.
Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs and small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes | Health Technology |
Prime Medicine, Inc.
 Prime Medicine, Inc. BiotechnologyHealth Technology Develops CRISPR gene editing technology | Health Technology |
